Results 31 to 40 of about 3,389 (131)

Zwitterionic Penicillin‐Derived Sulfone Inhibitor for Combating β‐Lactamase‐Mediated Antibiotic Resistance

open access: yesChemMedChem, Volume 21, Issue 9, 14 May 2026.
Combining enhanced permeability strategies with (2‐pyridyl)methylene substitution in the sulbactam scaffold led to a novel β‐lactamase inhibitor to combat β‐lactamase‐mediated resistance to β‐lactam antibiotics. The studies presented highlight the potential of compound 3 as a next‐generation β‐lactamase inhibitor for combating infections caused by ...
Diana Rodríguez   +4 more
wiley   +1 more source

Inactivation of the Pseudomonas-Derived Cephalosporinase-3 (PDC-3) by Relebactam

open access: yes, 2018
Pseudomonas aeruginosa is a prevalent and life-threatening Gram-negative pathogen. Pseudomonas -derived cephlosporinase (PDC) is the major inducible cephalosporinase in P. aeruginosa .
Krisztina M. Papp-Wallace   +6 more
core   +1 more source

Potentiation of imipenem by relebactam for Pseudomonas aeruginosa from bacteraemia and respiratory infections [PDF]

open access: yes, 2019
BACKGROUND: Imipenem resistance in Pseudomonas aeruginosa most often entails loss of the 'carbapenem-specific' porin OprD; more rarely it reflects acquired carbapenemases. Loss of OprD only confers resistance to imipenem if AmpC β-lactamase is expressed,
Livermore, David M.   +11 more
core   +1 more source

Genomic Insights Into Carbapenem‐Resistant Klebsiella pneumoniae in Pediatric Bloodstream Infections in Zhejiang, China (2019–2024)

open access: yesJournal of Clinical Laboratory Analysis, Volume 40, Issue 10, May 2026.
The primary mechanism of carbapenem resistance identified in pediatric CRKP‐BSI strains was the production of Class B metalloenzymes. We report, for the first time, an outbreak of bloodstream infections in a neonatal ward caused by the dissemination of NDM‐1‐producing ST25 K. pneumoniae.
Mingming Zhou   +8 more
wiley   +1 more source

Biomarkers of Drug‐Induced Kidney Injury: Use in Clinical Trials and Recent Examples of Impact on Drug Development

open access: yesClinical Pharmacology &Therapeutics, Volume 119, Issue 3, Page 608-617, March 2026.
This manuscript describes the scope of implementation and impact of a regulatory agency‐qualified panel of six urine biomarkers on drug development, the process for which was conducted and funded by the Critical Path Institute, the Foundation for the National Institutes of Health, and the United States Food and Drug Administration.
Tanja S. Zabka   +7 more
wiley   +1 more source

In Vitro Activity of Imipenem/Relebactam Alone and in Combination Against Cystic Fibrosis Isolates of Mycobacterium abscessus

open access: yes
Background: Mycobacterium abscessus (MABS) is an opportunistic pathogen that causes chronic, difficult-to-treat pulmonary infections, particularly in people with cystic fibrosis (PwCF), leading to rapid lung function decline and increased morbidity and ...
Aditi Shinde   +5 more
core   +1 more source

In Vitro Activity of Imipenem-Relebactam, Meropenem-Vaborbactam, Ceftazidime-Avibactam and Comparators on Carbapenem-Resistant Non-Carbapenemase-Producing Enterobacterales

open access: yes, 2023
Background: Avibactam, relebactam and vaborbactam are β-lactamase inhibitors that proved their efficiency against KPC-producing Enterobacterales. Regarding their inhibitor activity towards Ambler’s class A extended spectrum β-lactamases ...
Cécile Emeraud   +6 more
core   +1 more source

Reversing Antibiotic Resistance: Strategies From Adjuvants to Innovative Therapeutics

open access: yesMicrobiologyOpen, Volume 15, Issue 1, February 2026.
Molecular reversal strategies against antibiotic resistance act through three mechanisms: inhibiting resistance gene function, blocking horizontal gene transfer, and modulating host defense. Emerging technologies, such as CRISPR‐Cas gene editing, photodynamic therapy, nanotechnology, and ecological competition, further strengthen these approaches ...
Tianjiao Li   +4 more
wiley   +1 more source

Activity of imipenem/relebactam against Pseudomonas aeruginosa producing ESBLs and carbapenemases [PDF]

open access: yes, 2020
Background: ESBL- and carbapenemase-producing Pseudomonas aeruginosa are prevalent in, for example, the Middle East, Eastern Europe and Latin America, though rarer elsewhere. Because P. aeruginosa readily mutate to become carbapenem resistant via loss of
Vickers, Anna   +9 more
core   +1 more source

Carbapenem Resistance in India: A Systematic Review of Epidemiology, Diagnostic Strategies, and Therapeutic Approaches

open access: yesBioMed Research International, Volume 2026, Issue 1, 2026.
Background Carbapenem‐resistant gram‐negative infections pose a major public health challenge in India due to high antibiotic consumption, limited diagnostic access, and regional variation in resistance mechanisms. We systematically reviewed recent data to evaluate prevalence, diagnostics, and therapeutic strategies.
Akhil Kapoor   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy